Related Experiment Video
Updated: Aug 8, 2025
11:51
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
10.4K
Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure
Emerson C Perin1, Kenneth M Borow2, Timothy D Henry3
1Center for Clinical Research, The Texas Heart Institute, Houston, Texas, USA.
Journal of the American College of Cardiology
|March 1, 2023
Summary
Mesenchymal precursor cells (MPCs) did not meet the primary endpoint for heart failure with reduced ejection fraction (HFrEF). However, MPCs showed potential benefits in reducing cardiovascular events, particularly in patients with inflammation.
Area of Science:
- Cardiology
- Regenerative Medicine
- Immunology
Background:
- Mesenchymal precursor cells (MPCs) possess anti-inflammatory properties.
- MPCs are being investigated for their potential to improve outcomes in heart failure with reduced ejection fraction (HFrEF).
Purpose of the Study:
- To assess the efficacy and safety of MPCs in high-risk HFrEF patients.
- To evaluate the impact of MPCs on cardiovascular events and cardiac function.
Main Methods:
- A randomized, double-blind, multicenter study involving 565 HFrEF patients.
- Single transendocardial administration of MPCs versus sham-control.
- Primary endpoint: time to recurrent decompensated HFrEF events or ventricular arrhythmias.
Main Results:
- The primary endpoint was not significantly different between MPCs and control groups.
- MPCs improved left ventricular ejection fraction, particularly in patients with inflammation.
- MPCs significantly reduced the risk of myocardial infarction or stroke and major adverse cardiovascular events in specific subgroups.
Conclusions:
- The study did not meet its primary or secondary endpoints.
- Exploratory analyses suggest MPCs may benefit HFrEF patients with inflammation.
- Further research is warranted to explore MPCs' therapeutic potential in specific patient populations.
